3-氨基联苯-3-羧酸 | 124221-71-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-氨基联苯-3-羧酸
• 英文名称: 3'-Amino-[1,1'-biphenyl]-3-carboxylic acid
• 英文别名: 3-(3-aminophenyl)benzoic acid
• CAS: 124221-71-2
• 化学式: C₁₃H₁₁NO₂
• mdl: MFCD03839954
• 分子量: 213.23
• InChiKey: RQKFSJNOPKCEJI-UHFFFAOYSA-N

物化性质

• 沸点：
  476.9±38.0 °C(Predicted)
• 密度：
  1.257±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P233,P260,P261,P264,P270,P271,P280,P301+P312,P302+P352,P304,P304+P340,P305+P351+P338,P312,P321,P330,P332+P313,P337+P313,P340,P362,P403,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335

文献信息

• Cyclic derivatives as modulators of chemokine receptor activity
  申请人：Carter H. Percy

  公开号：US20050054627A1

  公开（公告）日：2005-03-10

  The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the treatment of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma.

  当前申请描述了MCP-1的调节剂，其化学公式为(I):或其药用可接受的盐形式，用于治疗类风湿性关节炎、多发性硬化症、动脉粥样硬化和哮喘。
• Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
  申请人：Carter H. Percy

  公开号：US20050054626A1

  公开（公告）日：2005-03-10

  The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.

  本申请描述了MCP-1的调节剂，化学式为(I)：或其药用可接受的盐形式，用于预防哮喘、多发性硬化症、动脉粥样硬化和类风湿性关节炎。
• Aromatic Monoester Compositions and Processes for Preparing Same
  申请人：ExxonMobil Chemical Patents Inc.

  公开号：US20180282257A1

  公开（公告）日：2018-10-04

  This disclosure relates to compositions that include one or more aromatic monoesters derived from branched Guerbet alcohols and aromatic acids, or from branched Guerbet acids and aromatic alcohols. The compositions are suitable as lubricant base stocks.

  本披露涉及包含一种或多种从分支Guerbet醇和芳香酸或从分支Guerbet酸和芳香醇中衍生出的芳香单酯的组合物。这些组合物适用作润滑油基础油。
• SOLABEGRON ZWITTERION AND USES THEREOF
  申请人：VELICEPT THERAPEUTICS, INC.

  公开号：US20180370902A1

  公开（公告）日：2018-12-27

  This application relates to solabegron zwitterion useful for the treatment of lower urinary tract symptoms such as, for example, overactive bladder and prostate disorders. Additionally, this application relates to pharmaceutical compositions and methods of treatment utilizing the solabegron zwitterion for treating lower urinary tract symptoms. This application also relates to methods of preparing solabegron hydrochloride from the solabegron zwitterion.

  本申请涉及可用于治疗下尿路症状，例如过度活跃的膀胱和前列腺疾病的索拉贝隆离子。此外，本申请涉及使用索拉贝隆离子治疗下尿路症状的制药组合物和治疗方法。本申请还涉及从索拉贝隆离子制备索拉贝隆盐酸盐的方法。
• Gastrin releasing peptide compounds
  申请人：Cappelletti Enrico

  公开号：US20060018830A1

  公开（公告）日：2006-01-26

  New and improved compounds for use in diagnostic imaging or therapy having the formula M-N—O—P-G, wherein M is a metal chelator having the structure: wherein R1-R5 and FG are as defined herein (in the form complexed with a metal radionuclide or not), N—O—P is the linker containing at least one non-alpha amino acid with a cyclic group, at least one substituted bile acid or at least one non-alpha amino acid, and G is the GRP receptor targeting peptide. In the preferred embodiment, M is an Aazta metal chelator or a derivative thereof. Methods for imaging a patient and/or providing radiotherapy or phototherapy to a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound is further provided. Methods and kits for preparing a radiotherapeutic agent are further provided.

  新的改进化合物用于诊断影像或治疗，其化学式为M-N—O—P-G，其中M是具有以下结构的金属螯合剂： 其中R1-R5和FG的定义如本文所述（以金属放射性核素或未配合的形式），N—O—P是含有至少一个非α氨基酸的连接剂，其中该氨基酸具有一个环形基团，至少一个取代的胆汁酸或至少一个非α氨基酸，而G是GRP受体靶向肽。在首选实施例中，M是Aazta金属螯合剂或其衍生物。还提供了使用该发明的化合物对患者进行成像和/或提供放射治疗或光疗的方法。还提供了制备诊断成像剂的方法和试剂盒。还提供了制备放射治疗剂的方法和试剂盒。